VIS-410

VIS-410 is an antibody inhibitor targeting the stem region of hemagglutinin (HA). VIS-410 inhibits influenza virus replication by blocking HA-mediated membrane fusion. VIS-410 exhibits broad-spectrum neutralization against influenza A viruses with group 1 and group 2 hemagglutinins, including subtypes such as H1N1, H3N2, H5N1, and H7N9 (H5N1 IC₅₀ = 1.5 μg/mL). VIS-410 is applicable to research related to influenza A virus infection ^{[1] [2]}.

In Vivo, VIS-410 (50 mg/kg; single dose, double dose) confers significant survival benefit in DBA mice infected with lethal H7N9 influenza A virus, and combination with Oseltamivir reduces lung viral load and cytokine responses^[2]. VIS-410 confers significant survival benefit in mice infected with H3N2 influenza A virus^[2].

In Vitro, VIS-410 potently inhibits replication of multiple influenza A virus strains (including H3N2 and H5N1) in MDCK cells, with IC₅₀ values ranging from 0.3-11 µg/mL, by blocking HA-mediated membrane fusion^[2]. VIS-410 exhibits an IC₅₀ of 1.5 μg/mL against Duck/MN/1525/81 H5N1^[2].

References:
[1]. Koszalka P, et al. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240-246.
[2]. Zeng LY, et al. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs. 2017;26(1):63-73.